益气除痰方联合安罗替尼治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Yiqi Chutan Formula Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：张景涛 田华琴[1] 陈学彰[1] 李宏良[1] 王斌[1] 朱志霞 陈锡康 丁洪刚 ZHANG Jing-tao;TIAN Hua-qin;CHEN Xue-zhang;LI Hong-liang;WANG Bin;ZHU Zhi-xia;CHEN Xi-kang;DING Hong-gang(Foshan Hospital of Traditional Chinese Medicine,Foshan 528000 Guangdong,China)

机构地区：[1]佛山市中医院,广东佛山528000

出　　处：《中医肿瘤学杂志》2023年第1期32-36,共5页Journal of Oncology in Chinese Medicine

基　　金：佛山市医学项目(编号:20220427)。

摘　　要：目的观察益气除痰方联合安罗替尼治疗晚期非小细胞肺癌的疗效及安全性。方法选取2022年1月至2022年8月间佛山市中医院治疗的40例晚期非小细胞肺癌患者。采取随机分组方法分为2组,对照组单纯口服安罗替尼进行治疗,治疗组在口服安罗替尼的基础上联合使用益气除痰方,2个疗程后,观察两组患者的疾病控制率,治疗前后的肿瘤标志物指标、卡氏评分、中医证候积分变化情况及不良反应。结果联合治疗组的疾病控制率是81.0%,对照组是73.7%,差异没有统计学意义(P>0.05),在降低肿瘤相关指标(CYFRA21-1、CEA、NSE)方面,治疗组优于对照组,差异具有统计学意义(P<0.05)。在中医证候积分及卡氏评分改善方面,治疗组优于对照组,差异具有统计学意义(P<0.05)。同时,治疗组的不良反应如高血压、手足皮肤反应、食欲减退等发生率显著低于对照组,差异具有统计学意义(P<0.05)。结论益气除痰方联合安罗替尼可以有效地改善晚期非小细胞肺癌患者生存质量,增强安罗替尼的疗效,降低安罗替尼的不良反应。Objective To observe the efficacy and safety of Yiqi Chutan Formula combined with anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 40 patients with advanced NSCLC who were treated in Foshan Hospital of Traditional Chinese Medicine from January 2022 to August 2022 were included into the trial.The patients were randomly divided into 2 groups.The control group was treated with anlotinib alone,and the treatment group was treated with Yiqi Chutan Formula combined with anlotinib.After 2 courses of treatment,disease control rate,the changes in the levels of tumor markers,KPS score,and TCM syndrome score,and the incidence of adverse reactions in the two groups were observed.Results The disease control rate of the treatment group was 81.0%,and that of the control group was 73.7%,the difference was not statistically significant(P>0.05).The treatment group had stronger effect on reducing the levels of tumor markers(CYFRA21-1,CEA,NSE)and on improving TCM symptom score and KPS score than the control group,and the differences were statistically significant(P<0.05).Moreover,the incidences of the adverse reactions of hypertension,hand-foot skin reaction,and loss of appetite in the treatment group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Yiqi Chutan Formula combined with anlotinib can effectively improve the quality of life of patients with advanced non-small cell lung cancer,enhance the efficacy of anlotinib,and reduce the adverse reactions of anlotinib.

关 键 词：益气除痰方 安罗替尼 晚期非小细胞肺癌 

分 类 号：R273[医药卫生—中西医结合] R734.2[医药卫生—中医肿瘤科]